- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Neuphoria Therapeutics Inc(NEUP)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for NEUP
11/13/2026: NEUP (1-star) is currently NOT-A-BUY. Pass it for now.
Neuphoria Therapeutics is a clinical-stage biotechnology company focused on developing novel treatments for central nervous system disorders, particularly through its lead candidate BNC210. While the company has developed a proprietary platform for ion channel modulation, it remains in a high-risk, pre-commercial stage with significant losses and no established revenue. Its primary investment story hinges on successful clinical trial execution and the potential realization of its merger with Scancell Holdings. Key risks include intense competition from large pharmaceutical incumbents, regulatory hurdles, and substantial financial execution pressure. This stock is best suited for speculative biotech investors who can tolerate extreme price volatility and monitor clinical outcomes closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | The company is in an early, high-risk clinical stage with no predictable growth trajectory. |
| Momentum investor | Mixed fit | Momentum is speculative and largely driven by M&A rumors or clinical trial event outcomes. |
| Value investor | Weak fit | The company is not currently profitable and lacks traditional valuation metrics. |
| Dividend investor | Weak fit | Neuphoria provides no income to shareholders and is focused on capital preservation and R&D. |
| Low-risk investor | Weak fit | The company's profile is high-risk due to clinical trial dependency and significant financial uncertainty. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock's small float and clinical-stage nature lead to extreme price sensitivity. |
| Valuation risk | High | Valuation is speculative and highly dependent on future clinical trial outcomes. |
| Competition risk (Pharma) | High | Large incumbents possess massive resources that can dwarf small biotech R&D efforts. |
| Business quality | Low | The business is pre-commercial and lacks established recurring revenue or profit margins. |
| Dividend income | Low / none | There is no dividend policy or expectation of income generation. |
| Execution risk | High | Success depends entirely on the clinical and regulatory execution of the BNC210 program. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.80M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 30.2K shares | Beta - | 52 Weeks Range 2.49 - 5.53 | Updated Date 11/14/2026 |
52 Weeks Range 2.49 - 5.53 | Updated Date 11/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.06 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Steep Decline
The stock price has dropped sharply with strong downward pressure.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -33.75% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development Licensing | Milestone payments and royalties from collaborative partnerships like Merck. | The company makes money primarily by licensing its science to bigger partners. |
| Clinical Research | Pipeline advancement for CNS disorders. | Currently, the company is spending cash to prove its drugs work. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value -5.87M | Price to Sales(TTM) 11.75 |
Enterprise Value -5.87M | Price to Sales(TTM) 11.75 | ||
Enterprise Value to Revenue 0.07 | Enterprise Value to EBITDA -0.06 | Shares Outstanding 5.41M | Shares Floating 5.37M |
Shares Outstanding 5.41M | Shares Floating 5.37M | ||
Percent Insiders 5.02 | Percent Institutions 42.22 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

